I don't see ESRX comments as newsworthy to sophisticated shareholders of either company. As you well know, WAG takes a big hit on the front end and ESRX deteriorates gradually for 2 years. The net effect is good for CVS and bad for WAG and ESRX. If ESRX/MHS merger goes through, ESRX may be facing several weak quarters. It's funny also that WAG, while attempting to move Part D business away from ESRX, is strongly promoting it's partnership with Coventry MPD which is a Medco product. Certainly a potential backfire there. The fact that they continue to push Coventry is part of the reason I think WAG plans to ink a contract. Either that or they think the merger won't happen. Time will tell.